Abstract
Nanocrystal budesonide (nanobudesonide) is a suspension for nebulization in patients with steroid-responsive pulmonary disease such as asthma. The pharmacokinetics and safety of the product were compared to those of Pulmicort ® Respules™. Sixteen healthy volunteers were administered nanobudesonide 0.5 and 1.0 mg, Pulmicort ® Respules™ 0.5 mg and placebo in a four-way, randomized crossover design. All nebulized formulations were well-tolerated, with no evidence of bronchospasm. Nebulization times were significantly shorter for nanobudesonide compared to Pulmicort ® Respules™. Because of a low oral bioavailability, plasma concentration of budesonide is a good marker of lung-delivered dose. The pharmacokinetics of nanobudesonide 0.5 and 1.0 mg were approximately dose proportional with respect to Cmax, AUC(0-t), and AUC(0-inf). Nanobudesonide 0.5 mg and Pulmicort ® Respules™ 0.5 mg exhibited similar AUC's, suggesting a similar extent of pulmonary absorption. A higher Cmax was noted with nanobudesonide 0.5 mg and the Tmax was significantly different, suggesting a more rapid rate of drug delivery of nanobudesonide 0.5 than Pulmicort ® Respules™.
In conclusion, nebulized nanobudesonide 0.5 mg was safe in healthy volunteers, with a similar extent of absorption as Pulmicort Respules.
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Inhaled anti-inflammatory corticosteroid therapy is an important component of the treatment regimen for chronic asthma. Practice guidelines recommend their use as firstline therapy for all cases of asthma, except mild intermittent asthma 1,2. The use of inhaled steroids early in the course of the disease is associated with improved outcomes compared to treatment with beta 2 adrenergic agonists. 3 Indeed, the early use of inhaled corticosteroids may alter the natural history of the disease 4 , and possibly reduce the irreversible airway obstruction associated with chronic inflammation of the lungs 5 .
Budesonide is a potent anti-inflammatory corticosteroid with low oral bioavailability. It forms reversible intracellular fatty acid esters in airway and lung tissue, which may prolong lung retention. 6 Budesonide is available as a dry powder inhaler (DPI) and as Pulmicort R Respules TM (AstraZeneca, Wilmington, DE), a suspension for inhalation with a jet-air 
METHODS

Subjects
Sixteen healthy volunteers (13 males and 3 females) with a mean age of 32.5 (range 25- 
Study Design
This was a randomized, double-blind, four-arm, single-dose cross-over study that compared the pharmacokinetics and safety of nanobudesonide and Pulmicort ® Respules TM .
The four study arms were (1) placebo, (2) 0.5 mg of Pulmicort R Respules treatments. The study protocol specified that each subject was to receive treatments not less than 5 or more than 10 days apart.
Spirometry, oximetry, clinical laboratory tests, ECG and vital signs were performed at baseline and at specified intervals. The spirometer was calibrated on a daily basis. Adverse events were monitored throughout the study. Twenty-four hours after each treatment, subjects were reevaluated and discharged from the unit.
Test Drugs and Administration
Nanobudesonide and placebo were manufactured by Automated Liquid Packaging, 
Statistical Analyses
Statistical analyses were performed using SAS ® Version 6.12 (SAS Institute, Cary, NC). transformed to the arithmetic scale. For untransformed data, treatments were compared for the 95% confidence intervals for the difference between means. For transformed data, a 95% confidence interval was calculated for the ratio of two means. Subjects were evaluated on an intent-to-treat basis, and those receiving at least one dose of the trial medication were included in analyses.
Safety variables of FEV1
RESULTS
Demographics
Sixteen subjects were enrolled and all completed the study. One subject exceeded the maximum ten day window permitted between treatment arm 3 and 4 by four days. This protocol variance did not jeopardize study integrity and this subject was included in the analysis.
Pharmacokinetics
This study compared the pharmacokinetics of Pulmicort ® and nanobudesonide delivered by inhalation ( Table 1) 
Nebulization Times and Residual Volumes
Nebulization was continued until 1 min after sputtering, which was not detected in one subject receiving Pulmicort ® Respules TM and one receiving 0.5 mg of nanobudesonide ( Table 2 ). The nebulization times for these subjects were 15 and 16 min, respectively. Seven subjects had residual volumes greater than 1.0 ml; 4 in the Pulmicort ® Respules TM group, 2 in the nanobudesonide 0.5 mg group, 1 in the nanobudesonide 1.0 mg group, and one in the placebo group. There was no clear relationship between higher residual volumes and longer nebulization times. Three subjects had residual volumes greater than 1.0 ml in more than one crossover treatment period.
Safety 9
There were no significant adverse effects associated with the administration of the test drugs. Four subjects reported a total of 8 adverse events after dosing with placebo. Two subjects reported a total of 4 adverse events (nausea, dizziness, paresthesia, and rhinitis) after dosing with Pulmicort ® Respules TM . One adverse event was reported with each of the nanobudesonide groups. These included rhinitis (nanobudesonide 0.5 mg) and edema at a venipuncture site (nanobudesonide 1.0 mg). All adverse effects were classified as mild.
There was no evidence of bronchospasm in any of the treatment arms. For FEV1, the overall treatment effect was not significant at any evaluation (p0.111). In addition, there were no clinically significant abnormalities in measured vital signs, pulse oximetry, electrocardiograms, or clinical laboratory tests.
DISCUSSION
Inhaled steroids are the preferred anti-inflammatory therapy in the treatment of asthma.
Budesonide delivered by nebulization is effective in controlling pediatric asthma, as measured using multiple clinical endpoints. 8, 9, 10, 11 The efficacy of inhaled budesonide is predominantly mediated by local action, with systemic absorption contributing little, if anything, to the control of inflammation in the lungs. 12 Budesonide has an excellent safety profile in children. Pediatric patients administered chronic inhaled steroids grow to a normal adult height. 13 However, safety concerns of a transient, decreased growth velocity in children 14 have resulted in under-utilization of inhaled corticosteroids in this age group. 15 The goal of the new nanocrystal formulation budesonide is to maximize efficiency of pulmonary delivery of drug, which may serve to obviate some of these safety concerns.
The delivery of budesonide by nebulization is a complex process that is affected by the characteristics of the nebulizer and compressor, droplet size, properties of the formulation, breathing pattern of the patient, and respiratory tree anatomy. A small component of the orally deposited drug may be absorbed through the buccal mucosa. This was minimized in the present study by the use of a mouthwash after nebulization. There is little or no metabolism of budesonide in the lung. 16 There is extensive hepatic first-pass metabolism of swallowed budesonide, with an oral bioavailability of ~11%. 17 Pharmacokinetic evaluation of drug absorption from the lungs, therefore, provides an accurate and reproducible method for comparing the dose delivered to the lung by different inhaler systems or different formulations from the same inhaler system .18,19 A Medline search for published reports of the pharmacokinetics of budesonide suspension delivered by a table- top nebulizer yielded a single report from a study in 10 children. 20 However, neither the budesonide particle size in the suspension nor the manufacturer of the suspension is specified in this European study. Data on file with AstraZeneca reports that in children with asthma, the Pari LC Jet Plus nebulizer with the Pari Master compressor delivered approximately 25% of labeled budesonide to the patient. 21 This delivered dose was comparable to that in healthy adults.
In this study of healthy volunteers, the 0.5 mg nanobudesonide and the 0. The comparable AUC, higher Cmax and lower Tmax of 0.5 mg nanobudesonide compared to 0.5 mg Pulmicort ® Respules™ suggests more rapid drug delivery, or more rapid absorption. If these differences are due to more rapid absorption, two mechanisms are possible. Nanobudesonide could have more rapid dissolution of the in the airways, or a more distal delivery of drug may facilitate rapid absorption. However, the PK data presented do not allow discrimination between these possibilities. Drug distribution studies will be required to determine the degree and kinetics of pulmonary deposition.
While some observations suggest that improved antiinflammatory drug distribution to small airways might result in increased clinical efficacy, 22 there is no clinical proof that this is the case. 23 Finally, results reported here in healthy adults should be extrapolated to other populations with caution. Budesonide clearance 20 and lung deposition 19, 24 differ in pediatric and adult populations. Additionally, drug delivery to the lungs will differ in asthmatic and healthy lungs. 25 The subjects in this study were not balanced with regard to gender and no subgroup analysis was performed owing to the small number (3) of females participating. However, no gender differences are present in the pharmacokinetic parameters of Pulmicort ® Respules™. 21 The potential for differential regional lung delivery of inhaled nanobudesonide based upon gender is unknown. 26 In conclusion, nanobudesonide exhibited pharmacokinetics that were dose-proportional, and nanobudesonide 0.5 mg yielded budesonide absorption that was comparable to Pulmicort ® Respules™. The higher Cmax and lower Tmax of 0.5 mg nanobudesonide suggests a more rapid rate of either drug delivery or absorption compared to Pulmicort ® Respules™. In addition, nanobudesonide administration demonstrated a safety profile that was comparable to Pulmicort ® Respules™. The significantly shorter nebulization time with nanobudesonide compared to Pulmicort ® Respules™ should be advantageous with respect to patient compliance. 
